American Journal of Physiology: Renal, Fluid & Electrolyte Physiology (Abstracts) 2014-12-15

Combination of ACE inhibitor with nicorandil provides further protection in chronic kidney disease.

Takeshi Shiraishi, Yoshifuru Tamura, Kei Taniguchi, Masato Higaki, Shuko Ueda, Tomoko Shima, Michito Nagura, Takahiko Nakagawa, Richard J Johnson, Shunya Uchida

文献索引：Am. J. Physiol. Renal Physiol. 307(12) , F1313-22, (2014)

全文：HTML全文

摘要

An inhibition in the renin-angiotensin system (RAS) is one of the most widely used therapies to treat chronic kidney disease. However, its effect is occasionally not sufficient and additional treatments may be required. Recently, we reported that nicorandil exhibited renoprotective effects in a mouse model of diabetic nephropathy. Here we examined if nicorandil can provide an additive protection on enalapril in chronic kidney disease. Single treatment with either enalapril or nicorandil significantly ameliorated glomerular and tubulointerstitial injury in the rat remnant kidney while the combination of these two compounds provided additive effects. In addition, an increase in oxidative stress in remnant kidney was also blocked by either enalapril or nicorandil while the combination of the drugs was more potent. A mechanism was likely due for nicorandil to preventing manganase superoxide dismutase (MnSOD) and sirtuin (Sirt)3 from being reduced in injured kidneys. A study with cultured podocytes indicated that the antioxidative effect could be mediated through sulfonylurea receptor (SUR) in the mitochondrial KATP channel since blocking SUR with glibenclamide reduced MnSOD and Sirt3 expression in podocytes. In conclusion, nicorandil may synergize with enalapril to provide superior protection in chronic kidney disease. Copyright © 2014 the American Physiological Society.